Jay Goldberg, MD, ob-gyn at Einstein Medical Center of Philadelphia, discusses treatment paradigms which can help clinicians manage abnormal uterine bleeding in their patients.
Contemporary OBGYN:
Please introduce yourself.
Jay Goldberg, MD:
Hi, I'm Jay Goldberg. I'm an ob-gyn from Philadelphia. I practice at Einstein Medical Center of Philadelphia, which is now part of the Jefferson Health System.
Contemporary OBGYN:
What are some of the clinical pearls of management of abnormal uterine bleeding?
Goldberg:
The talk that I gave on abnormal uterine bleeding discusses that abnormal bleeding is one of the most common reasons for women to present for a problem visit to their ob-gyn. It went through the PALM - COEIN acronym, which is an acronym that goes through different etiologies of abnormal uterine bleeding and [helps physicians] organize their thought process to come up with the correct diagnosis, and accordingly to treat the problem appropriately.
Contemporary OBGYN:
Is there any specific take-home treatment paradigm that you want clinicians to think about when they encounter abnormal bleeding?
Goldberg:
Yes, so ACOG’s reference is a good one to have. I think the important thing is to realize that whenever a woman presents with abnormal uterine bleeding, there may be many reasons for her to have the bleeding, and it's important to use the differential to try to come up with the diagnosis, both for diagnosis and for treatment.
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Study reveals critical gaps in care for PCOS patients
May 17th 2024A new study presented at the 2024 ACOG Annual Clinical and Scientific Meeting highlighted significant gaps in polycystic ovary syndrome (PCOS) care, revealing widespread patient dissatisfaction and the urgent need for improved provider education and comprehensive treatment approaches.
Read More
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.
Read More